Email Updates

Search form

You are here

23 FEBRUARY 2018 VOLUME 19 ISSUE 8

Media Coverage

  • Shortly after former South African President Jacob Zuma's election in 2009, The Lancet published the South Africa Series. At the time, life expectancy in the country had plummeted and the country was experiencing the effects of a widespread HIV epidemic after previous President Thabo Mbeki's denial of the existence of HIV. A change in leadership offered hope. As Zuma now steps down from office, facing scandals and allegations of corruption, this hope seems misplaced.

    February 24, 2018
    General
    Lancet
  • HIV, tuberculosis (TB) and sexually transmitted infections (STIs) have claimed too many South African lives. Today, defeating these diseases is a national priority, with the mission of the latest National Strategic Plan to get our country on track to eliminate them as public health threats by the year 2030. But what happens when the treatments we use to fight them no longer work?

    February 23, 2018
    General
    GroundUp
  • Science guided Switzerland away from prosecuting people living with HIV for theoretically exposing their partners to the virus. Could it happen here, too?

    February 22, 2018
    General
    The Body
  • Newly released figures from the Filippino health department have revealed that the number of HIV diagnoses has rocketed 3,147 percent over the past ten years in the country.

    February 22, 2018
    Pink News
  • For infants born with HIV, a rapid introduction to necessary treatment is often the lifeline between whether a child will live or die. The recent introduction of a life-saving, point-of-care diagnostic technology in sub-Saharan Africa could become a global solution to preventing infant deaths from HIV.

    February 22, 2018
    Devex
  • In both the movements to defeat HIV/AIDS and to reduce and eliminate gun violence, advocates have chiseled parallel entry points. For example, in the fight for firearms safety, people are contacting legislators, writing letters and newspaper editorials, forming study groups, and are engaging in other creative ways to raise issues.

    February 22, 2018
    General
    The Good Men Project
  • South Korea has approved the use of PrEP (Pre-Exposure Prophylaxis) in the country but it will cost users nearly $5,000 a year.

    February 21, 2018
    Pink News
  • Discrimination by insurance companies against people taking the drug Truvada as an effective HIV prevention method shows us that we still have a long way to go to educate insurers and other health officials about the realities of HIV-AIDS.

    February 21, 2018
    New York Times
  • The Philippines is facing the fastest-growing HIV epidemic in Asia Pacific—notably among young men—but the country’s president, Rodrigo Duterte told citizens to “avoid condoms because condoms aren’t pleasurable,” according to a translation from Rappler.

    February 20, 2018
    POZ
  • Kousalya was married at an age of 19 and by the time she turned 20, she was already a widow, HIV positive and thrown out of her marital home…..This is when she decided to fight for her rights and became the first woman in India to publicly disclose her HIV positive status. Today, over 30,000 HIV+ women and children are positively impacted by Kousalya’s amazing work.

    February 20, 2018
    General
    The Logical Indian
  • Mylan NV has announced that is its New Drug Application for the once-daily, fixed-dose combinations of dolutegravir, emtricitabine, and tenofovir alafenamide Tablets, 50 mg/200 mg/25 mg has received tentative approval from the US Food and Drug Administration under the US President's Emergency Plan for AIDS Relief. The antiretroviral will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

    February 20, 2018
    Contagion Live
  • Two Kericho infants put on the Mississippi Baby HIV ‘cure’ that electrified the world in 2013 are responding well, doctors have revealed.

    February 19, 2018
    Standard Digital
  • In The Lancet HIV, Beatriz Grinsztejn and colleagues report another first in Latin America: a demonstration trial of PrEP among MSM and transgender women vulnerable to HIV under real-world conditions in the Brazilian public health system.

    February 18, 2018
    Lancet HIV

Published Research

Announcements